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Hepatitis B virus (HBV) is one of the world’s major unconquered infections, resulting in
progressive liver disease, and current treatments rarely cure infection. A limitation to
discovering new therapies is our limited knowledge of HBV entry and dissemination
pathways that hinders the development of in vitro culture systems. To address this gap in our
understanding we optimized the genesis of infectious lentiviral pseudoparticles (HBVpps).
The recent discovery that the bile salt transporter sodium taurocholate co-transporting
polypeptide (NTCP) acts as a receptor for HBV enabled us to assess the receptor
dependency of HBVpp infection. HBVpps preferentially infect hepatoma cells expressing
NTCP, whereas other non-liver cells engineered to express NTCP do not support infection,
suggesting that additional hepatocyte-specific factors are required for HBVpp internalization.
These results highlight the value of the HBVpp system to dissect the pathways of HBV entry
and dissemination.
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Hepatitis B virus (HBV) infection is a major global health
problem frequently resulting in progressive, degenerative
liver disease, including cirrhosis and hepatocellular carcin-
oma. Despite the availability of a safe and effective vaccine,
and a range of nucleoside analogue antivirals,,240 million
people are chronically infected with HBV (El-Serag, 2012).
The high rate of viral turnover has resulted in vaccine-
related escape mutants and drug resistance (Billioud et al.,
2012; Locarnini & Yuen, 2010). Therefore, development of
safe, efficient antiviral strategies remains a key challenge
for the treatment of HBV.
A major obstacle to discovering new therapies is the lack of
efficient in vitro systems or small animal models supporting
HBV infection (Thomas & Zoulim, 2012). Our limited
knowledge of the host pathways regulating HBV entry
and dissemination hinders the development of model
systems that recapitulate the dynamics of HBV infection
and antigen expression in the liver. HBV infectivity is
dependent on the large (L) and surface (S) envelope
glycoproteins, with essential domains mapping to the
N-terminal 75 aa (Pre-S1) termed the ‘receptor binding
domain’ and to the antigenic ‘a’ loop of S (reviewed by
Baumert et al., 2014). A myristoylated peptide correspond-
ing to the N-terminal Pre-S1 region, Myrcludex B, inhibits
HBV infection (Volz et al., 2013) and was used as bait to
identify its host interacting partner as sodium taurocholate
co-transporting polypeptide (NTCP) (Ni et al., 2014; Yan
et al., 2012). NTCP (SLC10A1) is the founding member
of the SLC10 family of solute carrier proteins and is exclu-
sively expressed in hepatocytes, where it plays an important
role in bile acid uptake.
Although exogenous expression of NTCP in human hepa-
toma cells renders them susceptible to HBV infection, high
levels of viral inocula (100 genome copies per cell) and
polyethylene glycol are required to initiate replication
(Ni et al., 2014; Yan et al., 2012). As these infections require3These authors contributed equally to this paper.
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Fig. 1. HBV pseudovirus genesis. (a) HBVpps are produced by co-transfecting pNL4.3-luc-R2E2, a lentiviral HIV expression
vector, with replication-competent HBV genome H1.3 (genotype D) into parental Huh-7, NTCP-expressing hepatoma cells or
293T embryonal kidney cells. (b) The cells were cultured for 72 h, stained with mAb 18/7, specific for Pre-S1, and imaged
by confocal microscopy. Bar, 20 mm. (c, d) Extracellular expression of HBsAg or HIV p24 was quantified by ELISA. (e) To
evaluate HBV pseudovirus infectivity, the extracellular media (normalized for p24 content) was allowed to infect
dHepG2.NTCP cells for 72 h and luciferase activity measured. (f) Huh-7.NTCP cells were co-transfected with HBV genotype
A, C or D replication-competent genomes and pNL4.3-luc- R2E2; 72 h later the extracellular media was assessed for
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5–7 days to generate detectable antigen or viral genomes,
the current culture systems limit studies on HBV entry.
In order to develop a robust methodology to quantify HBV
entry we characterized lentivirus-based pseudoparticles
(HBVpps). This system has been used to study the entry
pathways of a range of viruses, including human immuno-
deficiency virus (HIV), hepatitis C virus (HCV), patho-
genic avian influenza and Ebola, offering a rapid and
reproducible analysis of the viral glycoprotein–receptor
interactions (Moller-Tank & Maury, 2015; Temperton
et al., 2007; Wright et al., 2009; Zimmer et al., 2014). Pre-
vious reports showed that lentiviral HBVpps were infec-
tious for human hepatocytes; however, given the limited
knowledge of internalization pathways at the time, the
receptor dependency was not studied (Chai et al., 2007;
Sung & Lai, 2002). Our studies show that infectious
HBVpp genesis is optimal in hepatoma cells, suggesting
that liver-specific factors are required for assembly and/or
infectivity. HBVpp entry is NTCP-dependent; however,
expression of NTCP in non-liver epithelial cells does not
confer permissivity to infection, suggesting that additional
hepatocyte-specific factors are required. The recent report
of a genetic polymorphism (p.Ser267Phe) in NTCP that
ablates HepG2 ability to support HBV infection in vitro
and yet supports HBV infection in man (Peng et al.,
2015) suggests that additional host factors are required
for HBV entry. Taken together, these results highlight the
utility of the pseudovirus approach to dissect the molecular
pathways of HBV entry into the liver.
Whilst there are several methods of generating pseudo-
viruses, we chose a luciferase-based HIV lentiviral system
(pNL4.3-luc-R2E2), similar to that reported for HCV
(Hsu et al., 2003) (Fig. 1a). For our initial studies we gener-
ated lentiviral pseudotypes using replication competent
HBV genomes to ensure that all three components of the
HBV surface proteins were expressed in a ratio and confor-
mation consistent with a native infection. Recent studies
show that both HepG2 and Huh-7 cells transduced to
express NTCP support HBV replication (Ni et al., 2014;
Yan et al., 2012); however, due to the low transfection effi-
ciency observed with HepG2 cells we selected Huh-7 cells to
generate lentiviral pseudoparticles. Parental Huh-7 or Huh-
7.NTCP cells were co-transfected with equal ratios of lenti-
virus pNL4.3-luc-R2E2 and replication-competent 1.3-fold
overlength HBV (H1.3) (genotype D) or a control ‘empty’
plasmid. The extracellular media collected after 72 h were
used to infect DMSO-differentiated HepG2.NTCP cells
(dHepG2.NTCP). HBV H1.3 and pNL4.3-luc-R2E2 plas-
mids were also transfected into human embryonal kidney
293T cells: this cell type is commonly used for pseudoparti-
cle genesis due to its high transfection efficiency; however, it
does not support HBV replication (Reese et al., 2013; Tang
et al., 2001). All of the transfected cells expressed comparable
levels of HBV Pre-S1 (Fig. 1b). Cellular processing and
secretion of HBV surface antigen-containing particles
(HBsAg) and HIV capsid protein p24 was confirmed by
ELISA (Fig. 1c, d). We observed significantly higher levels of
HBsAg secretion from 293T compared with Huh-7 and
Huh-7.NTCPcells.However, comparable levels of extracellular
HIV p24 were detected for all three cell lines (Fig. 1d), consist-
ent with similar levels of lentiviral core secretion.
Having established that both lentiviral capsid and HBV
particles are secreted, we measured the infectivity of pseudo-
virus preparations in dHepG2.NTCP cells. HBVpps produced
by hepatoma cells were 30- to 250-fold more infectious than
pseudovirus secreted from 293T cells (Fig. 1e), suggesting that
hepatocyte-specific factors play a role in the assembly and/or
secretion of infectious particles. All pseudotype preparations
were normalized for HIV p24 content for infection studies
and infectivity values represent the net luciferase activity
where the empty control virus activity is subtracted. Interest-
ingly, we noted that HBVpps produced from Huh-7.NTCP
cells were eightfold more infectious than virus generated by
parental Huh-7 cells (Fig. 1e). HBV Pre-S1 engagement of
NTCP has been reported to alter the expression of genes
involved in bile acid metabolism (Oehler et al., 2014), and
these pathways may play a role in promoting the assembly
and/or secretion of pseudoparticles.
To investigate whether pseudoviruses can be generated
expressing glycoproteins from diverse HBV genotypes we
co-transfected replication-competent HBV clones of geno-
type A, C and D with pNL4.3-luc-R2E2 into Huh-7.NTCP
and the extracellular virus used to infect dHepG2.NTCP.
All three genotypes expressed similar levels of HBsAg and
generated infectious pseudovirus; however, genotype D
was significantly more infectious than the other clones
tested (Fig. 1f). This observation suggests that increased
entry efficiency contributes to the enhanced infectivity of
genotype D virus observed in vitro.
To assess whether HBVpps are assembled we analysed viral
preparations by gradient centrifugation, and determined
infection of dHepG2.NTCP cells. (g) HBVpps or VSVpps were separated by density ultracentrifugation for 24 h at
100 000 g at 4 8C, across a 10–30 % iodixanol gradient, and each fraction assessed for HBsAg and p24 by ELISA or infec-
tion of dHepG2.NTCP cells. Results are the mean¡SD of three independent experiments. The no envelope control [500–
800 relative light units (RLU)] value was subtracted from the HBVpp RLU value and differences assessed by Student’s t-test
(*P,0.05, **P,0.01, ***P,0.001).
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Fig. 2. HBVpp entry is NTCP- and HBs-dependent. (a) HepG2 or HepG2.NTCP cells were tested for NTCP expression by
K9 anti-NTCP Western blotting or confocal microscopy. Bar, 10 mm. (b) Huh-7.NTCP cells were co-transfected with
replication-competent HBV genotype D or pcDNA3.1 encoding HBV-L and pNL4.3-luc-R2E2; 72 h later the extracellular
media were collected and assessed for infection of dHepG2 or dHepG2.NTCP cells. (c) Pseudoparticles generated from
HBV-L/pNL4.3-luc-R2E2 transfected Huh-7.NTCP producer cells were incubated with increasing doses of anti-HBs pooled
IgG or control irrelevant IgG for 1 h, before infecting dHepG2 or dHepG2.NTCP cells for 72 h; anti-HBs IgG inhibition (%)
is shown. (d) Pseudoparticles generated from HBV genotype A, C or D/pNL4.3-luc-R2E2 co-transfected Huh-7.NTCP
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whether HBsAg and lentiviral p24 locate in the same frac-
tion. HBVpps or control pseudoparticles expressing vesicu-
lar stomatitis virus G (VSVpp) generated from
Huh-7.NTCP cells were fractionated over 10–30 %
iodixanol gradients by ultracentrifugation at 100 000 g
for 24 h at 4 8C. Each fraction was assessed for HBsAg/
p24 by ELISA and for infectivity in dHepG2.NTCP cells.
HBsAg and p24 were detected in the same fractions, con-
sistent with the secretion of intact pseudoparticles and
infectivity of HBVpps and control VSVpps associated
with fractions between 18 and 22 % iodixanol (Fig. 1g),
demonstrating the assembly of HBs-containing lentiviral
pseudoparticles.
We assessed the ability of HBVpps to infect parental
HepG2 (NTCP null) and those transduced to express
NTCP, confirmed by quantitative real-time PCR measure-
ment of NTCP mRNA, anti-NTCP staining by Western
blot or confocal microscopy (Fig. 2a) and bile salt uptake
(data not shown). NTCP expression significantly enhanced
HBVpp infection (Fig. 2b), demonstrating common
receptor-dependent pathways with native HBV.
A significant caveat of generating HBVpps using replica-
tion-competent genomes is the concomitant production
of native HBV that will compete with pseudoparticles for
receptors and reduce reporter gene expression.
We therefore generated pseudovirus by co-transfecting
pcDNA3.1 encoding HBV L with the lentiviral vector and
observed similar levels of infection to those generated
with full-length HBV (Fig. 2b). To confirm that pseudo-
particle infection was dependent on HBV glycoprotein
expression we investigated the ability of a clinical-grade
polyclonal IgG pooled from vaccinated donors (Hepatect)
to neutralize infection. HBVpps were incubated for 1 h
with increasing doses of Hepatect or an irrelevant IgG,
before inoculating dHepG2 or dHepG2.NTCP cells.
We observed a dose-dependent inhibition of HBVpp infec-
tion (Fig. 2c), demonstrating that HBVpp infection is HBs-
dependent. The low-level HBVpp infection observed in par-
ental HepG2 cells was neutralized by Hepatect, suggesting
an alternative NTCP-independent route for pseudoparticle
entry. Hepatect also neutralized the infectivity of HBVpps
expressing genotype A- and C-encoded glycoproteins
(Fig. 2d), confirming HBs-dependent routes of infection
for all pseudotypes.
To confirm the role of NTCP in HBVpp entry, we assessed
the ability of Myrcludex B to inhibit pseudoparticle infect-
ivity. dHepG2 or dHepG2.NTCP cells were incubated with
1 mM Myrcludex B, Hepatect (1 : 10) or an irrelevant
immunoglobulin, or a combination of both for 1 h prior
to infecting with HBVpps or VSVpps. Myrcludex signifi-
cantly inhibited HBVpp infection of dHepG2.NTCP and
we noted an additive effect of combining Myrcludex with
Hepatect to neutralize HBVpp infection (Fig. 2e). Myrclu-
dex or Hepatect had no effect on VSVpp infection (data
not shown).
To investigate whether HBVpps show a restricted tropism
for liver-derived cells we measured their ability to infect
three liver-derived cell lines (Huh-7, HepG2 and Hep3B)
and two non-liver epithelial cell lines [293T (embryonal
kidney) and A549 (lung epithelial)] in the presence or
absence of exogenous NTCP expression. As a control, we
included pseudoparticles that could only infect hepatocytes
(HCVpps) or showed broad-range tropism (VSVpps). All
cell lines were confirmed to express NTCP by binding flu-
orescent-labelled Myrcludex (Fig. 3a) or K9 anti-NTCP
staining (Fig. 3b). HBVpps only infected the hepatoma
lines and NTCP expression increased entry in all cases
(Fig. 3c). In contrast, HBVpps did not infect 293T or
A549 cells in the presence or absence of NTCP, suggesting
that NTCP expression alone is not sufficient to confer
HBVpp entry and that additional hepatocyte specific fac-
tors are required. HCVpps only infected Huh-7 and
Hep3B cells, as previously reported (Hsu et al., 2003),
and NTCP expression had no effect (Fig. 3b).
As expected given its broad tropism, VSVpps infected all
cells types with high efficiency in an NTCP-independent
manner, demonstrating efficient HIV LTR-driven reporter
activity in all cell lines studied.
In conclusion, we have optimized the genesis of infectious
HBVpps, enabling quantitative studies on HBV entry that
are independent of downstream HBV replication events.
The HBV surface glycoprotein is unlike other viral glyco-
proteins tested to date (Moller-Tank & Maury, 2015;
Temperton et al., 2007; Wright et al., 2009; Zimmer
et al., 2014) in its failure to produce infectious pseudo-
particles in human embryonal kidney cells (293T), requir-
ing a liver cell background for infectious particles genesis.
Our results show that whilst NTCP does play an essential
role in HBVpp entry, it is unlikely to be the sole receptor
facilitating infection. The recent study by Verrier et al.
(2015) highlighting a role for Glypican 5, a heparin sul-
phate moiety that is highly expressed in the liver, in
HBV and HDV infection supports our conclusions.
Taken together, these results highlight the value of the
HBVpp system to dissect the pathways of HBV entry
producer cells were incubated with anti-HBs (1 : 100 dilution) or control IgG for 1 h prior to infecting dHepG2 or
dHepG2.NTCP cells for 72 h. (e) dHepG2 or HepG2.NTCP were treated with Myrcludex B (Myr B) (1 mM), anti-HBs
immunoglobulin (Ig) (1 : 10 dilution) or irrelevant immunoglobulin for 1 h before infecting with HBVpp genotype D for 72 h
before quantifying infection. Results are the mean¡SD of at least three experiments, with differences assessed using
Student’s t-test (*P,0.05, **P,0.01, ***P,0.001).
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Fig. 3. NTCP expression alone is not sufficient to confer HBVpp infection of non-hepatic cells. (a) Hepatocyte-derived
(Huh-7, HepG2, Hep3B) and non-liver embryonal kidney (293T) or lung (A549) epithelial cells were transduced to express
NTCP and expression was confirmed by staining with fluorescent-labelled HBV Pre-S1 peptide. (b) NTCP expression was
quantified by flow cytometry using K9 anti-NTCP and irrelevant control immunoglobulin, where the data are expressed as
mean fluorescence intensity (MFI) of K9 staining and the irrelevant immunoglobulin value subtracted. (c) Parental and NTCP-
expressing cell lines were infected with HBVpp generated from HBV-L and pNL4.3-luc-R2E2 transfected Huh-7.NTCP cells,
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and dissemination, and will aid in the discovery of new
antiviral agents.
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